Supercharge Immuno-Oncology Drug Discovery
Deliver Results in Days, Not Months with the BD FACSDiscover™ Platform
Immuno-oncology has revolutionized cancer treatment, offering patients more targeted and effective options that avoid the toxic side effects of traditional chemotherapy and radiation. Drug discovery in this rapidly evolving field is becoming increasingly complex as our understanding of biology deepens. Traditional flow cytometry tools and techniques, however, often miss crucial biological nuances, hindering innovation and slowing the development of advanced therapies.
Drive Drug Discovery with Confidence
The BD FACSDiscover™ A8 Cell Analyzer and BD FACSDiscover™ S8 Cell Sorter with BD SpectralFX™ Technology and BD CellView™ Image Technology are transforming immuno-oncology drug discovery by uniquely integrating spectral flow cytometry, real-time spatial information and image-enabled cell sorting. This unprecedented combination empowers researchers to accelerate and de-risk the development of next-generation cancer therapies.
Choose the BD FACSDiscover™ Platform to:
-
Expand your discovery potential with a new dimension
Add spatial data to your flow cytometry experiments with BD CellView™ Image Technology and move beyond surface marker expression to understand function not just phenotype. -
Accelerate and de-risk your discovery timelines
Scale without sacrificing precision, make more confident go/no-go decisions and de-risk your pipeline by ensuring only the most promising candidates and targets move forward. -
Achieve reproducible results with out-of-the-box standardization
Get straight to discovery with advanced flow cytometers that are ready out of the box—no manual detector voltage gains adjustments required in most cases. Designed for consistency and ease, they deliver reliable, high-quality data for your longitudinal and/or multi-site studies regardless of who runs the experiment or which system you use.
Spatial Dimension in Flow
Cancers are complex diseases. Understanding their etiology and developing effective drug targets requires advanced tools that can reveal the intricacies of tumor microenvironments, capture functional readouts and detect shifts in cell states.
Where traditional flow cytometry relied on one dimension – signal intensity – and delivered primarily phenotypic data, real-time imaging flow cytometry on the BD FACSDiscover™ Platform now adds an additional spatial dimension that can provide functional information that reveals complex biological phenomena and enables workflows that were previously impossible.
Move Beyond Surface Marker Expression to Understand Function not Just Phenotype
The BD FACSDiscover™ A8 Cell Analyzer and BD FACSDiscover™ S8 Cell Sorter provide the analytical depth indispensable to advanced immuno-oncology drug discovery programs by combining state-of-the-art spectral flow cytometry with the spatial and functional insights delivered by real-time imaging using BD CellView™ Image Technology.
The unique combination of spectral flow cytometry, spatial information and image-guided cell sorting found only in BD FACSDiscover™ Platform helps you to:
- Measure multiple functional readouts, such as
- NFκB nuclear translocation, T-cell exhaustion, and checkpoint expression, in the same assay
- Detect subtle shifts in cellular states such as nuclear condensation and fragmentation, membrane changes, cell cycle stages, immune synapse formation and DNA damage
- Visualize morphological differences across cell types to guide targeted sorting
This allows you to uncover biological dynamics that drive disease etiology, determine how cellular populations interact with and respond to drugs or biomarkers, rapidly linking mechanistic biology to translational endpoints. Importantly, this breadth of discovery in imaging based screens, can be achieved in days, not months, ultimately accelerating the transition into preclinical and clinical research phases.
Bring New Images to Flow
Find out how leading flow cytometry core labs are using real-time image flow cytometry on the BD FACSDiscover™ S8 Cell Sorter to (1) sort phagocytosing cells based on spatial distribution of fluorescence signal, (2) achieve cleaner sort resolution of solid samples and (3) sort cells by all major mitotic phases.
Accelerate & De-risk Discovery
Time is money, and the drug discovery process in immuno-oncology is particularly time-consuming, expensive and risky. Solutions that rapidly deliver robust, high-parameter data can enable more confident go/no-go decisions, helping to decrease costs, improve success rates and de-risk the discovery process, ultimately accelerating the delivery of safe, efficacious drugs to patients.
Cut Weeks and Months from Your Discovery Timelines
The BD FACSDiscover™ A8 Cell Analyzer and BD FACSDiscover™ S8 Cell Sorter can reduce development time and increase the efficiency of your drug development programs through:
- An integrated plate and tube sample autoloader on the BD FACSDiscover™ A8 Cell Analyzer that offers walkaway automation to support large-scale screening (e.g., CRISPR, phenotypic, or checkpoint assays) without compromising precision
- Real-time imaging that reduces the need for separate microscopy-based validation of targets and biomarkers
- Enhanced sensitivity and spectral unmixing paired with real-time imaging that delivers clean, reproducible data to minimize false positives and facilitate faster and more confident decision making
- Spectral clarity and image-guided sorting that ensure only the most biologically relevant cell populations are moved forward in the drug discovery workflow
Minimize False Positives and Make More Confident Decisions
In this experiment we demonstrate how combining spatial insights and spectral immunophenotyping on the BD FACSDiscover™ A8 Cell Analyzer enables deep immunophenotyping at scale. We show how you can run 2,700 unique populations on a single plate in less than 40 minutes to identify distinct phenotypic visual patterns of immune cell activation markers dependent on subpopulation and stimulation conditions.
In this webinar, Raffaello Cimbro, Director and Global Leader of Flow Cytometry at AstraZeneca discusses how merging real-time imaging with spectral flow cytometry improves the quality and efficiency of cell analysis and enables his team to advancing drug discovery by sorting cells based on their morphology and protein localization.
Immune cell doublets: Unveiling secrets with real-time imaging flow cytometry
Cell doublets are routinely detected in the analysis of human immune cells from blood and tissue preparations, yet they are commonly excluded from data acquisition and/or analysis as they are believed to be technical artifacts resulting from ex vivo sample manipulation. However, this blanket exclusion ignores the fact that highly conserved biological mechanisms rely on direct cellular contact and that cell doublets may be windows into those processes.
In this on-demand webinar, Julie Burel, PhD from the Center for Vaccine Innovation at the La Jolla Institute for Immunology shares how their team has discovered that human blood-derived immune cell doublets exhibit imaging, molecular and cellular signatures consistent with known biological processes, and that their frequency and phenotype fluctuates during infection and vaccination. Thus, some cell doublets might reflect biologically meaningful interactions, making their study highly valuable.
Using real-time imaging flow cytometry can help reveal complex biological phenomena and enable workflows that were previously impossible. Sorting based on GFP used to be one dimensional, either GFP+ or GFP- based on signal intensity. Now, you can leverage BD CellView™ Image Technology to make more informed decisions and utilize spatial information to confidently isolate your cells of interest.
Standardization
Standardization helps drug discovery programs minimize costly setbacks and compare results across studies and platforms. However, achieving this standardization using traditional flow cytometry is time consuming and anything but trivial. Inconsistencies between instruments—both in the same laboratory space and across sites—as well as differences in experiment setup by users on the same instrument introduce variability and necessitate additional experiments to support and validate results.
Out-of-the-Box Standardization and Reproducibility
The BD FACSDiscover™ A8 Cell Analyzer and BD FACSDiscover™ S8 Cell Sorter provide the perfect platform for robust, standardized and reproducible analysis, screening and sorting. Expect out-of-the box consistency in the data acquired at default gains—day-to-day and instrument-to-instrument, for all your assays. No complex instrument setups, no unintuitive software, and no need for trial-and-error approaches to find the correct optical detector gain settings. Simply unbox and begin to make discoveries.
This is enabled by:
- Exceptional instrument detector standardization that enables you to achieve reproducibility across multiple data generation sites without tedious, time-consuming and resource-intensive procedures.
- Instrument detectors that are calibrated using an onboard LED pulser, resulting in precise and accurate detector setting adjustment and performance.
- The ability to run a wide range of experiments in default mode, which minimizes the need for the user to adjust gain settings and helps obtain unmixing results with less spread.
Inter-Instrument Data Consistency
Expect consistency in the data acquired at default gains instrument-to-instrument for all your assays.
BD FACSDiscover™ Spectral Flow Cytometers with Real-time Imaging Parameters
Meet the BD FACSDiscover™ family of instruments, the world's first matched-pair spectral analyzer and sorter with real-time imaging. Equipped with state-of-the-art BD SpectralFX™ Technology and revolutionary BD CellView™ Image Technology, these cytometers redefine biological research. Step into a new era of scientific discovery with the BD FACSDiscover™ Platform.
BD FACSDiscover™ A8 Cell Analyzer | BD FACSDiscover™ S8 Cell Sorter |
|
|
| Learn More > | Learn More > |
Speak to an Expert
*Required fields
BD flow cytometers are Class 1 Laser Products.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.